Article info
Editor's choice
Highlights from this issue
Citation
Highlights from this issue
Publication history
- First published January 18, 2012.
Online issue publication
January 18, 2012
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
- Changes to anti-JCV antibody levels in a Swedish national MS cohort
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
- MRI pattern in asymptomatic natalizumab-associated PML
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS